人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版)

2021-05-11 中国临床肿瘤学会 中华医学杂志.2021.101(17):1226-1231.

人表皮生长因子受体2(HER2)阳性乳腺癌临床占比20%左右。近年来,针对HER2的生物靶向药物成为治疗乳腺癌的重要突破。近年来,帕妥珠单抗、拉帕替尼、吡咯替尼和恩美曲妥珠单抗(T‑DM1)等新的抗H

中文标题:

人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版)

发布机构:

中国临床肿瘤学会

发布日期:

2021-05-11

简要介绍:

人表皮生长因子受体2(HER2)阳性乳腺癌临床占比20%左右。近年来,针对HER2的生物靶向药物成为治疗乳腺癌的重要突破。近年来,帕妥珠单抗、拉帕替尼、吡咯替尼和恩美曲妥珠单抗(T‑DM1)等新的抗HER2药物不断研发成功上市,在HER2阳性乳腺癌的治疗中取得良好效果,改变了临床实践。但规范治疗是保证相关疗效的前提,为了更好地规范HER2阳性乳腺癌临床合理诊疗,做到“合适人群、合理时机、合适方案”,中国临床肿瘤学会乳腺癌专家委员会和中国抗癌协会乳腺癌专业委员会,根据2016年发表的“人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识”及《中国临床肿瘤学会乳腺癌诊疗指南》,结合近期国内外研究进展进行了更新,以供国内外同道参考。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=412cc1c0021118f0, title=人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版), enTitle=, guiderFrom=中华医学杂志.2021.101(17):1226-1231., authorId=0, author=, summary=人表皮生长因子受体2(HER2)阳性乳腺癌临床占比20%左右。近年来,针对HER2的生物靶向药物成为治疗乳腺癌的重要突破。近年来,帕妥珠单抗、拉帕替尼、吡咯替尼和恩美曲妥珠单抗(T‑DM1)等新的抗H, cover=https://img.medsci.cn/202166/1622988429873_2020535.jpg, journalId=0, articlesId=null, associationId=863, associationName=中国临床肿瘤学会, associationIntro=null, copyright=0, guiderPublishedTime=Tue May 11 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>人表皮生长因子受体2(HER2)阳性乳腺癌临床占比20%左右。近年来,针对HER2的生物靶向药物成为治疗乳腺癌的重要突破。近年来,帕妥珠单抗、拉帕替尼、吡咯替尼和恩美曲妥珠单抗(T‑DM1)等新的抗HER2药物不断研发成功上市,在HER2阳性乳腺癌的治疗中取得良好效果,改变了临床实践。但规范治疗是保证相关疗效的前提,为了更好地规范HER2阳性乳腺癌临床合理诊疗,做到&ldquo;合适人群、合理时机、合适方案&rdquo;,中国临床肿瘤学会乳腺癌专家委员会和中国抗癌协会乳腺癌专业委员会,根据2016年发表的&ldquo;人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识&rdquo;及《中国临床肿瘤学会乳腺癌诊疗指南》,结合近期国内外研究进展进行了更新,以供国内外同道参考。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=285, tagName=乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=285, guiderKeyword=乳腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=15418, appHits=279, showAppHits=0, pcHits=1344, showPcHits=15139, likes=1, shares=16, comments=17, approvalStatus=1, publishedTime=Sun Jun 06 22:26:23 CST 2021, publishedTimeString=2021-05-11, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Jun 06 22:07:34 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Wed Jan 03 09:43:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版).pdf)])
人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版).pdf
下载请点击:
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207559, encodeId=4929120e559d0, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:07:32 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196472, encodeId=534311964e226, content=good , beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47db6484545, createdName=ms7000002115301694, createdTime=Wed Feb 23 16:58:17 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062497, encodeId=4375106249ef7, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Thu Oct 21 09:04:05 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062128, encodeId=4ad0106212818, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa355503943, createdName=MARBU, createdTime=Wed Oct 20 00:06:46 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061126, encodeId=53281061126cb, content=非常好,👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b12884021, createdName=1921987096, createdTime=Sat Oct 16 22:43:42 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2022-03-31 ms2000001047258750

    good

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207559, encodeId=4929120e559d0, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:07:32 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196472, encodeId=534311964e226, content=good , beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47db6484545, createdName=ms7000002115301694, createdTime=Wed Feb 23 16:58:17 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062497, encodeId=4375106249ef7, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Thu Oct 21 09:04:05 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062128, encodeId=4ad0106212818, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa355503943, createdName=MARBU, createdTime=Wed Oct 20 00:06:46 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061126, encodeId=53281061126cb, content=非常好,👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b12884021, createdName=1921987096, createdTime=Sat Oct 16 22:43:42 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2022-02-23 ms7000002115301694

    good

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1207559, encodeId=4929120e559d0, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:07:32 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196472, encodeId=534311964e226, content=good , beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47db6484545, createdName=ms7000002115301694, createdTime=Wed Feb 23 16:58:17 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062497, encodeId=4375106249ef7, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Thu Oct 21 09:04:05 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062128, encodeId=4ad0106212818, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa355503943, createdName=MARBU, createdTime=Wed Oct 20 00:06:46 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061126, encodeId=53281061126cb, content=非常好,👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b12884021, createdName=1921987096, createdTime=Sat Oct 16 22:43:42 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-21 ms4000000670558531

    good

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1207559, encodeId=4929120e559d0, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:07:32 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196472, encodeId=534311964e226, content=good , beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47db6484545, createdName=ms7000002115301694, createdTime=Wed Feb 23 16:58:17 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062497, encodeId=4375106249ef7, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Thu Oct 21 09:04:05 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062128, encodeId=4ad0106212818, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa355503943, createdName=MARBU, createdTime=Wed Oct 20 00:06:46 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061126, encodeId=53281061126cb, content=非常好,👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b12884021, createdName=1921987096, createdTime=Sat Oct 16 22:43:42 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-20 MARBU

    非常好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1207559, encodeId=4929120e559d0, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:07:32 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196472, encodeId=534311964e226, content=good , beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47db6484545, createdName=ms7000002115301694, createdTime=Wed Feb 23 16:58:17 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062497, encodeId=4375106249ef7, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Thu Oct 21 09:04:05 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062128, encodeId=4ad0106212818, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa355503943, createdName=MARBU, createdTime=Wed Oct 20 00:06:46 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061126, encodeId=53281061126cb, content=非常好,👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b12884021, createdName=1921987096, createdTime=Sat Oct 16 22:43:42 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 1921987096

    非常好,👍

    0

拓展阅读

乳腺癌HER2检测指南(2009版)

中国肿瘤科相关专家小组(统称) · 2009-12-01

2010 乳腺癌骨转移和骨相关疾病临床诊疗专家共识(2010版)

乳腺癌骨转移和骨相关疾病临床诊疗专家组 · 2010-01-01

2010 SBI/ACR推荐建议:乳腺癌影像学筛查

乳腺影像学会(SBI,Society of Breast Imaging) · 2010-01-20

2010 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2010-02-01

2010 ASCO-CAP指南:乳腺癌患者雌激素和雄激素受体的免疫组化检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-04-19

2010 ASCO指南:激素受体阳性乳腺癌妇女的辅助内分泌治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-07-12